A response to: Letter to the editor regarding "Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis"
| dc.contributor.author | Ismaila, AS | |
| dc.contributor.author | Haeussler, K | |
| dc.contributor.author | Malmenäs, M | |
| dc.contributor.author | Sharma, R | |
| dc.contributor.author | Compton, C | |
| dc.contributor.author | Vogelmeier, CF | |
| dc.contributor.author | Han, MK | |
| dc.contributor.author | Halpin, DMG | |
| dc.date.accessioned | 2023-06-22T12:01:19Z | |
| dc.date.issued | 2023-04-01 | |
| dc.date.updated | 2023-06-20T08:16:59Z | |
| dc.format.extent | 2556-2561 | |
| dc.identifier.citation | Vol. 40, No. 5, pp. 2556-2561 | en_GB |
| dc.identifier.doi | https://doi.org/10.1007/s12325-023-02495-0 | |
| dc.identifier.uri | http://hdl.handle.net/10871/133475 | |
| dc.identifier | ORCID: 0000-0003-2009-4406 (Halpin, David MG) | |
| dc.language.iso | en | en_GB |
| dc.publisher | Springer | en_GB |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/37004642 | en_GB |
| dc.rights | © The Author(s) 2023. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. | en_GB |
| dc.subject | COPD | en_GB |
| dc.subject | Chlorobenzenes | en_GB |
| dc.title | A response to: Letter to the editor regarding "Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis" | en_GB |
| dc.type | Article | en_GB |
| dc.date.available | 2023-06-22T12:01:19Z | |
| dc.identifier.issn | 0741-238X | |
| exeter.place-of-publication | United States | |
| dc.description | This is the final version. Available on open access from Springer via the DOI in this record. | en_GB |
| dc.description | Data Availability: The datasets analyzed during the current study are available from the corresponding author on reasonable request. | en_GB |
| dc.identifier.eissn | 1865-8652 | |
| dc.identifier.journal | Advances in Therapy | en_GB |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
| dcterms.dateAccepted | 2023-03-09 | |
| rioxxterms.version | VoR | en_GB |
| rioxxterms.licenseref.startdate | 2023-04-01 | |
| rioxxterms.type | Journal Article/Review | en_GB |
| refterms.dateFCD | 2023-06-22T11:57:52Z | |
| refterms.versionFCD | VoR | |
| refterms.dateFOA | 2023-06-22T12:01:26Z | |
| refterms.panel | A | en_GB |
| refterms.dateFirstOnline | 2023-04-01 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2023. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.